Targeting B cells in the treatment of childhood-onset systemic lupus erythematosus
- 1 May 2006
- journal article
- editorial
- Published by Elsevier in The Journal of Pediatrics
- Vol. 148 (5) , 571-573
- https://doi.org/10.1016/j.jpeds.2006.03.011
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Rituximab therapy for childhood-onset systemic lupus erythematosusThe Journal of Pediatrics, 2006
- B lymphocyte depletion therapy in children with refractory systemic lupus erythematosusArthritis & Rheumatism, 2005
- Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: An open‐label trialArthritis & Rheumatism, 2005
- Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosusArthritis & Rheumatism, 2004
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2003
- Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosusArthritis & Rheumatism, 2003
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 2003
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- The central and multiple roles of B cells in lupus pathogenesisImmunological Reviews, 1999